Hunan Er Kang Pharmaceutical
Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's finished drugs primarily comprise sulbenicillin sodium for i… Read more
Hunan Er Kang Pharmaceutical (300267) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: 0.034x
Based on the latest financial reports, Hunan Er Kang Pharmaceutical (300267) has a cash flow conversion efficiency ratio of 0.034x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥174.55 Million) by net assets (CN¥5.09 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hunan Er Kang Pharmaceutical - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Hunan Er Kang Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hunan Er Kang Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hunan Er Kang Pharmaceutical ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BELRISE INDUSTRIES LTD
NSE:BELRISE
|
0.011x |
|
Beyond, Inc.
NASDAQ:BYON
|
0.121x |
|
Shore Bancshares Inc
NASDAQ:SHBI
|
0.072x |
|
Ramkrishna Forgings Limited
NSE:RKFORGE
|
-0.002x |
|
Taiyuan Heavy Industry Co Ltd
SHG:600169
|
0.080x |
|
VITASOY INTL
MU:VS6
|
0.080x |
|
Henan Tong-Da Cable Co Ltd
SHE:002560
|
0.104x |
|
SIA ENGINEERING CO.
F:O3H
|
N/A |
Annual Cash Flow Conversion Efficiency for Hunan Er Kang Pharmaceutical (2008–2024)
The table below shows the annual cash flow conversion efficiency of Hunan Er Kang Pharmaceutical from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥4.40 Billion | CN¥166.69 Million | 0.038x | +22.71% |
| 2023-12-31 | CN¥4.81 Billion | CN¥148.42 Million | 0.031x | -44.54% |
| 2022-12-31 | CN¥5.05 Billion | CN¥281.02 Million | 0.056x | +192.56% |
| 2021-12-31 | CN¥4.87 Billion | CN¥92.68 Million | 0.019x | -38.29% |
| 2020-12-31 | CN¥5.79 Billion | CN¥178.53 Million | 0.031x | -59.96% |
| 2019-12-31 | CN¥5.79 Billion | CN¥445.82 Million | 0.077x | +250.28% |
| 2018-12-31 | CN¥5.64 Billion | CN¥123.89 Million | 0.022x | -82.75% |
| 2017-12-31 | CN¥5.41 Billion | CN¥689.11 Million | 0.127x | +37.27% |
| 2016-12-31 | CN¥5.24 Billion | CN¥486.50 Million | 0.093x | -23.90% |
| 2015-12-31 | CN¥4.26 Billion | CN¥518.96 Million | 0.122x | +16.62% |
| 2014-12-31 | CN¥1.68 Billion | CN¥175.38 Million | 0.105x | -19.97% |
| 2013-12-31 | CN¥1.33 Billion | CN¥174.22 Million | 0.131x | +80.97% |
| 2012-12-31 | CN¥1.16 Billion | CN¥84.02 Million | 0.072x | +1.24% |
| 2011-12-31 | CN¥1.06 Billion | CN¥75.72 Million | 0.071x | -70.36% |
| 2010-12-31 | CN¥176.62 Million | CN¥42.47 Million | 0.240x | +159.86% |
| 2009-12-31 | CN¥110.01 Million | CN¥10.18 Million | 0.093x | +2663.24% |
| 2008-12-31 | CN¥63.01 Million | CN¥211.00K | 0.003x | -- |